Show simple item record

dc.contributor.authorSpecka, Michael
dc.contributor.authorKuhlmann, Thomas
dc.contributor.authorBonnet, Udo
dc.contributor.authorSawazki, Jürgen
dc.contributor.authorSchaaf, Luzia
dc.contributor.authorKühnhold, Stefan
dc.contributor.authorSteinert, Renate
dc.contributor.authorGrigoleit, Torsten
dc.contributor.authorEich, Helmut
dc.contributor.authorZeiske, Benita
dc.contributor.authorNiedersteberg, Antje
dc.contributor.authorSteiner, Katharina
dc.contributor.authorSchifano, Fabrizio
dc.contributor.authorScherbaum, Norbert
dc.date.accessioned2022-06-16T11:00:03Z
dc.date.available2022-06-16T11:00:03Z
dc.date.issued2022-06-01
dc.identifier.citationSpecka , M , Kuhlmann , T , Bonnet , U , Sawazki , J , Schaaf , L , Kühnhold , S , Steinert , R , Grigoleit , T , Eich , H , Zeiske , B , Niedersteberg , A , Steiner , K , Schifano , F & Scherbaum , N 2022 , ' Novel Synthetic Opioids (NSO) Use in Opioid Dependents Entering Detoxification Treatment ' , Frontiers in Psychiatry , vol. 13 , 868346 . https://doi.org/10.3389/fpsyt.2022.868346
dc.identifier.issn1664-0640
dc.identifier.otherPURE: 27200722
dc.identifier.otherPURE UUID: fa1c32bb-2574-4106-b3fc-dab4cac7cbfa
dc.identifier.otherJisc: 390616
dc.identifier.otherJisc: 390616
dc.identifier.urihttp://hdl.handle.net/2299/25559
dc.description© 2022 Specka, Kuhlmann, Bonnet, Sawazki, Schaaf, Kühnhold, Steinert, Grigoleit, Eich, Zeiske, Niedersteberg, Steiner, Schifano and Scherbaum. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). https://creativecommons.org/licenses/by/4.0/
dc.description.abstractIntroduction: Over the last decade, the use of New/Novel Synthetic Opioids (NSO) has emerged as an increasing problem, and especially so in the USA. However, only little is known about the prevalence and history of NSO use in European heroin dependents. Method: A cross-sectional multicenter study, carried out with the means of both standardized interviews and urine toxicology enhanced screening, in a sample of opioid addicted patients referred for an in-patient detoxification treatment. Results: Sample size included here n = 256 patients; prior to admission, 63.7% were prescribed with an opioid maintenance treatment. Lifetime use of heroin and opioid analgesics was reported by 99.2 and 30.4%, respectively. Lifetime NSO/fentanyl use was reported by 8.7% (n = 22); a regular use was reported by 1.6% (n = 4), and ingestion over the 30 days prior to admission by 0.8% (n = 2). Most typically, patients had started with a regular consumption of heroin, followed by maintenance opioids; opioid analgesics; and by NSO. Self-reported data were corroborated by the toxicology screenings carried out; no evidence was here identified for the presence of heroin being contaminated by fentanyl/derivatives. Discussion: NSO and also opioid analgesics did not play a relevant role in the development and the course of opioid/opioid use disorders in German patients referred for an inpatient detoxification treatment.en
dc.language.isoeng
dc.relation.ispartofFrontiers in Psychiatry
dc.subjectPsychiatry
dc.subjectnew synthetic opioids
dc.subjectfentanyl
dc.subjectfentanyl analogs
dc.subjectinpatient detoxification
dc.subjectopioids
dc.subjectopioid dependence
dc.titleNovel Synthetic Opioids (NSO) Use in Opioid Dependents Entering Detoxification Treatmenten
dc.contributor.institutionDepartment of Clinical, Pharmaceutical and Biological Science
dc.contributor.institutionCentre for Health Services and Clinical Research
dc.contributor.institutionPsychopharmacology, Drug Misuse and Novel Psychoactive Substances Unit
dc.contributor.institutionSchool of Life and Medical Sciences
dc.description.statusPeer reviewed
rioxxterms.versionVoR
rioxxterms.versionofrecordhttps://doi.org/10.3389/fpsyt.2022.868346
rioxxterms.typeJournal Article/Review
herts.preservation.rarelyaccessedtrue


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record